Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Voyager Therapeutics Inc VYGR

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:VYGR)

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

GlobeNewswire 1 hour ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

GlobeNewswire 13 days ago

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

GlobeNewswire April 16, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 26, 2024

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

GlobeNewswire March 13, 2024

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire February 28, 2024

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

GlobeNewswire February 26, 2024

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

GlobeNewswire February 21, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

GlobeNewswire February 20, 2024

Opinion & Analysis (NDAQ:VYGR)

No current opinion is available.

Bullboard Posts (NDAQ:VYGR)

Voyager Therapeutics Enters Capsid License Agreement and Str

News; $VYGR Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene...
whytestocks - January 2, 2024

VYGR ..... still here and building a position

Cheers !
Iseneschal - November 30, 2021

VYGR ...... still climbing....moderately.....

N.H.O.D
Iseneschal - November 19, 2021

VYGR ..... up on early a.m NR.....

Volume is light....not "Prime TIme" Cheers !
Iseneschal - November 19, 2021

VYGR ..... bot the dip.......now let's see the rip ?

Over $4
Iseneschal - November 17, 2021

VYGR ...... What did I say yesterday?

Ya gotta buy the f'ing dips....... Cheers !
Iseneschal - November 10, 2021